Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 372 participants found THC's brain effects are dose-dependent and track with CB1 receptor density across regions
Strong evidence · 7 studies
Meta-analysis limited to studies using acute THC challenges under experimental conditions, which may not fully represent chronic use patterns. Individual variation in receptor density was not captured
Controlled trial shows smoking and vaping deliver cannabis identically to blood, identifies potential biomarkers for recent use, and proposes detection cutoffs under 8 hours
Strong evidence · 6 studies
The study used a single THC dose (50.6 mg). Real-world consumption varies widely in dose and potency. The sample size was relatively small. The proposed cutoffs need validation in larger populations a
A controlled trial found low-dose CBD enhanced THC intoxication while high-dose CBD reduced it, with the strongest effects in infrequent cannabis users
Strong evidence · 6 studies
Relatively small sample (n=36). Predominantly male (31/36). Vaporization delivery may not generalize to other routes. Only two CBD doses tested, so the threshold for switching from enhancement to redu
Where questions remain
Controlled study of 23 marijuana users found varying CBC and CBD concentrations did not change the effects of smoked marijuana, confirming THC as the primary active ingredient
Moderate evidence · 25 studies
The CBD and CBC concentrations tested were relatively low compared to some cannabis preparations. The study used only two THC dose levels that may not have been different enough to detect dose-depende
In 24 non-daily users, cognitive and motor impairment increased linearly with THC dose (up to 69 mg), but some individuals showed no motor impairment even at blood THC above 40 ng/mL
Moderate evidence · 25 studies
Only 24 non-daily male users were studied. Experienced daily users might show different dose-response patterns due to tolerance. The controlled smoking protocol may not reflect real-world consumption.
Analysis of 140+ herbal incense products from 2008-2009 showed manufacturers rapidly switched synthetic cannabinoid ingredients in response to German bans, making contents unpredictable for consumers
Moderate evidence · 25 studies
German market may not reflect products in other countries. Analytical methods may not have detected all possible adulterants. The study could not assess health consequences of the identified compounds
A commentary argued for harm reduction through product composition changes, specifically reducing THC and increasing CBD in cannabis to lower psychosis and addiction risks
Moderate evidence · 25 studies
Commentary piece rather than original research. The practical feasibility of regulating cannabis composition was not fully addressed. The dissolved oxygen/alcohol proposal had limited evidence.
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Where THC acts in the brain depends on dose and how many cannabinoid receptors are present
Identifying where THC acts most strongly in the brain, and why, helps explain the wide range of cognitive effects reported by cannabis users and could inform dosing strategies for therapeutic applications.
Alpha-Pinene Does Not Counteract THC-Induced Memory Impairment in Humans
This rigorous trial found no evidence for one of the most commonly cited entourage effect claims.
Blood and oral fluid cannabinoid levels varied widely between frequent and occasional cannabis smokers
Several states have adopted per se THC driving limits, but this study shows these limits perform poorly at identifying recent use, especially in frequent users who may test positive without having used recently. This has direct implications for roadside testing fairness.
Oral cannabis at 25-50 mg THC markedly impaired cognition in infrequent users, with delayed onset and peak effects
Edibles are a growing market segment, but their delayed onset leads to overconsumption. This controlled study quantifies the dose-response and time course, providing the evidence base for edible dosing guidelines and consumer education.
Cannabis edibles produced delayed, lower blood THC peaks than smoking, with women showing higher concentrations
This is one of the few controlled studies with both sexes examining oral cannabis pharmacokinetics. The sex differences (higher THC in women) and oral fluid findings (immediate detection not reflecting blood levels) have direct implications for drug testing interpretation.
Low-dose CBD enhanced THC intoxication while high-dose CBD reduced it, especially in infrequent users
This fundamentally challenges the simple narrative that "CBD counteracts THC." The dose matters enormously, and low-dose CBD (the ratio found in many commercial products) may actually make THC more intoxicating.
How the research developed
2000–2009
3 studies published. Includes 2 RCTs, 1 strong-evidence studies.
2010–2014
6 studies published. Predominantly observational and review studies.
2015–2019
35 studies published. Includes 7 RCTs, 4 strong-evidence studies.
2020–present
108 studies published. Includes 1 meta-analyses, 7 RCTs, 22 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 152 peer-reviewed studies: 1 meta-analyses (1%), 16 randomized controlled trials (11%), 66 observational studies (43%), 29 reviews (19%), 9 case studies (6%), 31 other study types (20%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.